ZURZUVAE Drug Patent Profile

Which patents cover Zurzuvae, and what generic alternatives are available?

Zurzuvae is a drug marketed by Biogen Inc and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and twenty-one patent family members in thirty-seven countries.

The generic ingredient in ZURZUVAE is zuranolone. One supplier is listed for this compound. Additional details are available on the zuranolone profile page.

DrugPatentWatch^® Generic Entry Outlook for Zurzuvae

Zurzuvae will be eligible for patent challenges on October 31, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 31, 2028. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZURZUVAE

International Patents:	121
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	25
Drug Prices:	Drug price information for ZURZUVAE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZURZUVAE
What excipients (inactive ingredients) are in ZURZUVAE?	ZURZUVAE excipients list
DailyMed Link:	ZURZUVAE at DailyMed

See drug prices for ZURZUVAE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZURZUVAE

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

217369

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZURZUVAE

Drug Class	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator
Mechanism of Action	GABA A Receptor Positive Modulators

US Patents and Regulatory Information for ZURZUVAE

ZURZUVAE is protected by five US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biogen Inc	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369-001	Oct 31, 2023		RX	Yes	No	11,884,696
Biogen Inc	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369-003	Oct 31, 2023		RX	Yes	Yes
Biogen Inc	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369-002	Oct 31, 2023		RX	Yes	No	11,884,696
Biogen Inc	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369-001	Oct 31, 2023		RX	Yes	No	9,512,165		Y	Y
Biogen Inc	ZURZUVAE	zuranolone	CAPSULE;ORAL	217369-002	Oct 31, 2023		RX	Yes	No

International Patents for ZURZUVAE

See the table below for patents covering ZURZUVAE around the world.

Country	Patent Number	Title	Estimated Expiration
Philippines	12019500375	A CRYSTALLINE 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID
China	118754924	19-去甲C3,3-二取代的C21-N-吡唑基类固醇及其使用方法 (19-norC3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof)
Jordan	P20190022
Mexico	2022007490	ESTEROIDES C21-N-PIRAZOLILO 19-NOR C3,3- DISUSTITUIDOS Y METODOS DE USO DE LOS MISMOS. (19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF.)
Singapore	11201508550X	19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF

Market Dynamics and Financial Trajectory for ZURZUVAE

Last updated: July 28, 2025

---

Introduction

ZURZUVAE (zuranolone) has emerged as a significant development within the pharmaceutical landscape, targeting postpartum depression (PPD)—a condition affecting approximately 10-15% of women postpartum, with considerable economic and social implications. Approved by the FDA in August 2023, ZURZUVAE represents a novel oral neuroactive steroid designed to rapidly alleviate depressive symptoms. This analysis explores the market dynamics influencing ZURZUVAE’s adoption, its competitive landscape, regulatory environment, and the projected financial trajectory over coming years.

---

Market Landscape

Prevalence and Unmet Needs

Postpartum depression is underdiagnosed and undertreated, partly due to stigma and lack of effective, fast-acting therapies. Currently, the standard of care involves SSRIs and psychotherapy, which often have delayed onset of action and variable efficacy [1]. The unmet clinical need for rapid, effective treatments creates a substantial opportunity for ZURZUVAE, positioning it as a potential first-line treatment for PPD.

Market Size and Growth Potential

The global postpartum depression market was valued at approximately USD 500 million in 2022 and is expected to grow at a CAGR exceeding 15% through 2030, driven by increased awareness, diagnosis rates, and approvals of novel therapies [2]. In the U.S., the primary market for ZURZUVAE, the postpartum population comprises roughly 4 million births annually, translating into a significant patient base.

Competitive Landscape

While ZURZUVAE faces competition from traditional antidepressants and off-label use of existing drugs, its unique mechanism—modulation of GABA receptors via neuroactive steroids—positions it distinctly. Pharmaceutics such as Sage Therapeutics' brexanolone (Zulresso) have set precedents, with Zulresso approved in 2019 for PPD but hindered by high cost and administerable via IV, limiting utility [3]. ZURZUVAE's oral administration offers advantages in convenience and potentially broader adoption.

Key competitors include:

• Brexanolone (Zulresso): For IV infusion, high cost, and inpatient administration.
• Sage’s SAGE-217 (Zuranolone): An oral drug under review for major depressive disorder and PPD.
• Emerging generic and biosimilar players: Varying efficacy and safety profiles.

Positioning: ZURZUVAE's oral route and rapid onset suggest potential for greater market penetration, especially if safety and efficacy are comparable or superior.

---

Regulatory and Clinical Development Dynamics

Regulatory Milestones

Following ZURZUVAE's FDA approval in August 2023, subsequent regulatory activities—such as formulary listings, insurance reimbursements, and clinician education—will be pivotal. The drug’s safety profile, demonstrated in pivotal trials, reportedly showed rapid symptom relief with a favorable tolerability profile, bolstering its commercial prospects [4].

Clinical Trial Insights

Phase 3 trials revealed ZURZUVAE's promising efficacy; particularly, rapid symptom improvement within days. The studies utilized standardized scales such as the Edinburgh Postnatal Depression Scale (EPDS), affirming statistically significant benefits over placebo.

Market Adoption Challenges

Potential hurdles include clinician familiarity, reimbursement dynamics, and patient acceptance. Insurance coverage negotiations, particularly for high-cost therapies, will influence prescribing patterns.

---

Financial Trajectory and Forecast

Initial Revenue Outlook

Post-launch, ZURZUVAE's revenues are projected to reach USD 300-500 million within the first three years, contingent on market uptake and competitive responses [5]. Early adoption is likely in specialized postpartum clinics, with gradual expansion into primary care.

Pricing Strategy and Reimbursement

Pricing will be critical; if set competitively around USD 15,000-20,000 per course—similar to Zulresso—reimbursement will hinge on demonstrated cost-effectiveness and payer acceptance.

Long-Term Revenue Growth

Given the sizable and expanding target population, ZURZUVAE's revenues could approach USD 1 billion annually if it captures a substantial share of the PPD treatment market by 2030. Additional indications, such as treatment-resistant depression, could further diversify revenue streams.

R&D and Pipeline Considerations

Ongoing clinical trials for related neuroactive steroids may extend ZURZUVAE’s indications, supporting sustained growth and pipeline expansion.

---

Market Dynamics Influencing Financial Trajectory

• Healthcare System Approvals and Reimbursement Policies: Favorable CMS and private insurer coverage will accelerate adoption.
• Physician and Patient Acceptance: Education campaigns emphasizing rapid onset and ease of oral dosing will be vital.
• Patent Life and Market Exclusivity: Patents expiring around 2035 could invite generics or biosimilars, impacting pricing.
• Evolving Competitor Strategies: Innovations from rivals—such as longer-acting formulations or combination therapies—may influence ZURZUVAE's market share.

---

Conclusion

ZURZUVAE's approval marks a transformative moment in PPD management. Its unique oral formulation, coupled with rapid symptomatic relief, aligns with market demands for accessible, effective therapies. Financial forecasts indicate robust growth potential, especially if reimbursement hurdles are navigated successfully and clinician awareness grows. The landscape remains competitive, yet ZURZUVAE’s differentiated profile affords it a strategic advantage.

---

Key Takeaways

• Market potential for ZURZUVAE is substantial, driven by high unmet clinical needs in postpartum depression treatment.
• Competitive edge lies in oral administration and rapid efficacy, differentiating ZURZUVAE from injectable alternatives like Zulresso.
• Regulatory and reimbursement success regions will be critical to maximize revenue; proactive engagement with payers and healthcare providers is essential.
• Long-term growth hinges on expanding indications, maintaining patent exclusivity, and navigating market competition.
• Strategic positioning post-launch will determine market penetration, with clinician education and patient acceptance playing pivotal roles.

---

FAQs

1. What distinguishes ZURZUVAE from existing postpartum depression treatments?
ZURZUVAE offers an oral, rapidly acting therapy targeting neuroactive steroid pathways, contrasting with IV-administered therapies like Zulresso and delayed-acting SSRIs.

2. What is the expected timeline for ZURZUVAE’s market penetration?
Initial uptake in specialized clinics is anticipated within the first 6-12 months post-approval, with broader primary care adoption potentially within 2-3 years.

3. How does ZURZUVAE's pricing impact its market adoption?
Pricing at comparable levels to Zulresso (~USD 20,000 per course) could challenge reimbursement but may be offset by convenience and comparable efficacy. Negotiations with payers will influence patient access.

4. Are there additional indications for ZURZUVAE beyond postpartum depression?
Potential expansion into major depressive disorder and treatment-resistant depression exists, supported by ongoing clinical trials and the drug’s mechanism of action.

5. What risks could impede ZURZUVAE’s financial success?
Competitive pressures, high costs, reimbursement obstacles, and unforeseen safety issues post-marketing could limit market share and revenue.

---

References
[1] American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders.
[2] Grand View Research. (2022). Postpartum depression market size, share & trends analysis.
[3] Sage Therapeutics. (2019). Zulresso (brexanolone) FDA approval details.
[4] ClinicalTrials.gov. (2023). ZURZUVAE pivotal trial results.
[5] MarketWatch. (2023). Forecasts for neuroactive steroids in postpartum depression.

Note: All data are based on publicly available information as of early 2023.